A novel immunoadsorbent for rheumatoid arthritis therapy--preparation and efficacy evaluation

Artif Cells Blood Substit Immobil Biotechnol. 2000 Sep;28(5):409-14. doi: 10.3109/10731190009118585.

Abstract

Aim: To develop a novel immunoadsorbent for rheumatoid arthritis (RA) therapy.

Methods: A RA immunoadsorbent was developed by binding heat-aggregated human IgG(HAHIgG) to porous agar gel beads. Its adsorption capacity for rheumatoid factors (RFs), storage stability and blood compatibility were evaluated.

Results: The coupling yield of HAHIgG on the carrier was 6.0 mg/g wet gel. Saturation adsorption capacity of the adsorbent for IgMRF, IgGRF and IgARF were 3400, 2240 and 2400 IU/g, respectively. The adsorbent can be stored at 4 degrees C for three months without significant variance in its activity. Its fine permeability and hemocompatibility were demonstrated by extracorporeal hemoperfusion on rabbits.

Conclusion: HAHIgG/agar gel is a safe and effective immunoadsorbent for RA therapy, its potential clinical use is promising in the future.

MeSH terms

  • Agar
  • Animals
  • Arthritis, Rheumatoid / blood
  • Arthritis, Rheumatoid / therapy*
  • Dose-Response Relationship, Drug
  • Drug Storage
  • Hemoperfusion
  • Humans
  • Immunoglobulin G / metabolism
  • Immunosorbent Techniques
  • Immunosorbents / adverse effects
  • Immunosorbents / metabolism
  • Immunosorbents / therapeutic use*
  • Protein Binding
  • Rabbits
  • Rheumatoid Factor / blood
  • Rheumatoid Factor / metabolism

Substances

  • Immunoglobulin G
  • Immunosorbents
  • Agar
  • Rheumatoid Factor